Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 35

Results For "2023"

1144 News Found

Aster’s India and GCC business separation nearing completion
Healthcare | March 20, 2024

Aster’s India and GCC business separation nearing completion

The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value


Carbogen Amcis (Shanghai) completed ANVISA Audit
Drug Approval | March 19, 2024

Carbogen Amcis (Shanghai) completed ANVISA Audit

A five-day inspection was concluded successfully with no critical and no major observations raised


Sumitomo Pharma announces availability of ORGOVYX in Canada
News | March 17, 2024

Sumitomo Pharma announces availability of ORGOVYX in Canada

The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer


Evonik Vland Biotech JV commences operations
Biotech | March 16, 2024

Evonik Vland Biotech JV commences operations

Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China


European Commission approves Pfizer’s Prevenar 20 to help protect infants and children against pneumococcal disease
Drug Approval | March 13, 2024

European Commission approves Pfizer’s Prevenar 20 to help protect infants and children against pneumococcal disease

PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally


USFDA grants orphan drug and pediatric exclusivities for Cresemba for aspergillosis and mucormycosis in children
Drug Approval | March 12, 2024

USFDA grants orphan drug and pediatric exclusivities for Cresemba for aspergillosis and mucormycosis in children

CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications


Briefs: Zydus Lifesciences and Rainbow Children's Medicare
News | March 11, 2024

Briefs: Zydus Lifesciences and Rainbow Children's Medicare

Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility


EMA validates MAAs for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in two types of cancer
Drug Approval | March 07, 2024

EMA validates MAAs for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in two types of cancer

The validations confirm the completion of the applications and commence the scientific review process


Sakar's oncology unit receives EU GMP approval
Drug Approval | March 07, 2024

Sakar's oncology unit receives EU GMP approval

The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters